116140-28-4

Basic information

• Product Name: ethyl 5-phenylnicotinate
• Synonyms: ethyl 5-phenylnicotinate;ethyl 5-phenylnicotinate(WXC06549)
• CAS NO: 116140-28-4
• Molecular Formula: C₁₄H₁₃NO₂
• Molecular Weight: 227.25852
• Mol File: 116140-28-4.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 5-phenylnicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 5-phenylnicotinate(116140-28-4)
• EPA Substance Registry System: ethyl 5-phenylnicotinate(116140-28-4)

Safety Data

• Hazardous Substances Data: 116140-28-4(Hazardous Substances Data)

Upstream product

• 64-17-5 ethanol 
• 10177-11-4 5-phenylnicotinonitrile 
• 39620-02-5 5-bromonicotinoyl chloride 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 20986-40-7 ethyl 5-bromo-3-pyridinecarboxylate 
• 98-80-6 phenylboronic acid 
• 591-51-5 phenyllithium 
• 100-58-3 phenylmagnesium bromide 
• 1261785-72-1 C₁₂H₈ClNO 
• 10177-12-5 5-phenylnicotinic acid 
• 342024-50-4 methyl 5-triflatonicotinate 
• 100-59-4 phenylmagnesium chloride 

Downstream Products

• 187392-96-7 3-hydroxymethyl-5-phenyl-pyridine 
• 1193238-00-4 phenyl-5 nipecotate d'ethyle 
• 116140-30-8 chlorhydrate de l'acide phenyl-5 nipecotique 

Relevant articles and documents

Preparation of polyfunctional pyridines by a palladium(0)-catalyzed cross-coupling of functionalized aryl Grignard reagents

Difunctionalized pyridines can be prepared by a Pd(0)-catalyzed cross-coupling of functionalized arylmagnesium compounds with chloro- or bromopyridines at temperatures as low as -40°C. An addition-elimination mechanism involving a palladate intermediate is proposed.

Five-membered azole heterocyclic compound and its preparation method, pharmaceutical composition and use thereof

The present invention relates to a five-membered azole heterocycle compound represented by the following general formula (I), a preparation method of the five-membered azole heterocycle compound, a drug composition of the five-membered azole heterocycle compound, and a use of the five-membered azole heterocycle compound in preparation of drugs for prevention or treatment of TGR5-mediated diseases. The formula (I) is represented by the instruction.

Synthesis and evaluation of a conditionally-silent agonist for the α7 nicotinic acetylcholine receptor

We introduce the term 'silent agonists' to describe ligands that can place the α7 nicotinic acetylcholine receptor (nAChR) into a desensitized state with little or no apparent activation of the ion channel, forming a complex that can subsequently generate